MedTrace Logo

SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

NCT03604211 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2018-08-17

No results posted yet for this study

Summary

Single-institution retrospective analysis for predictive factors of prostate cancer patients presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.

Conditions

Interventions

RADIATION

Cyberknife Radiation Therapy

Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy

Sponsors & Collaborators

  • Swiss Cancer Institute

    collaborator OTHER

  • Kantonsspital Graubuenden

    lead OTHER

Principal Investigators

  • Daniel R Zwahlen, MD · Kantonsspital Graubuenden

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2015-07-31
Completion
2018-07-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03604211 on ClinicalTrials.gov